4,7-Dimethoxyflavone

4,7-Dimethoxyflavone

SCHEMBL3470601

COc1ccc(-c2cc(=O)c3ccc(OC)cc3o2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 1.00
CYP3A4 P08684 6/20 0.83
TP53 P04637 5/20 0.83
KDM4E B2RXH2 5/20 0.83
ALDH1A1 P00352 5/20 0.83
HPGD P15428 5/20 0.83
MAPT P10636 5/20 0.83
HSD17B10 Q99714 4/20 0.83
MEN1 O00255 4/20 0.83
KMT2A Q03164 4/20 0.83
CYP2C9 P11712 3/20 0.83
CYP2C19 P33261 3/20 0.83
CYP2D6 P10635 2/20 0.83
TNKS O95271 3/20 0.83
CYP19A1 P11511 1/20 0.83
TNKS2 Q9H2K2 1/20 0.81
SMN1; SMN2 Q16637 3/20 0.80
NPC1 O15118 3/20 0.80
RAB9A P51151 3/20 0.80
LMNA P02545 2/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28154767 0.91 MAOB (0.86) MAOBCYP3A4TP53KDM4EALDH1A1
SCHEMBL30674795 0.91 MAOB (0.83) MAOBCYP3A4TP53KDM4EALDH1A1
SCHEMBL312254 0.91 CYP3A4 (1.00) MAOBCYP3A4TP53KDM4EALDH1A1
SCHEMBL30266579 0.91 CYP3A4 (1.00) MAOBCYP3A4TP53KDM4EALDH1A1
SCHEMBL9142214 0.91 MAOB (1.00) MAOBCYP3A4TP53KDM4EALDH1A1
SCHEMBL7656355 0.91 MAOB (0.83) MAOBCYP3A4TP53KDM4EALDH1A1
SCHEMBL30674786 0.91 MAOB (1.00) MAOBCYP3A4TP53KDM4EALDH1A1
7-Methoxyflavone SCHEMBL1373009 0.91 TNKS (1.00) MAOBCYP3A4TP53KDM4EALDH1A1
SCHEMBL534596 0.90 CYP3A4 (1.00) MAOBCYP3A4TP53KDM4EALDH1A1
SCHEMBL31364277 0.90 MAOB (0.81) MAOBCYP3A4TP53KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240269066-A1 USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING XEROPHTHALMIA PRECVISION BIOTECHNOLOGIES LTD. (CN) 2024-08-15 US claimed
EP-4353264-A1 USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME Precvision Biotechnologies Ltd. (CN) 2024-04-17 EP claimed
CN-117561081-A Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia 广州珍实视界生物医药科技有限公司 2024-02-13 CN claimed
WO-2022257986-A1 USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME 广州岐微生物医药科技有限公司 2022-12-15 WO claimed
US-20100303937-A1 NOVEL COMPOSITION TO INCREASE TESTOSTERONE LEVELS BENOIT & COTE (CA) 2010-12-02 US claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
CN-114031656-B Medicine for treating urinary system lithiasis related diseases and preparation method thereof 张弘 2025-05-27 CN disclosed
US-20240269066-A1 USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING XEROPHTHALMIA PRECVISION BIOTECHNOLOGIES LTD. (CN) 2024-08-15 US disclosed
EP-4353264-A1 USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME Precvision Biotechnologies Ltd. (CN) 2024-04-17 EP disclosed
CN-117561081-A Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia 广州珍实视界生物医药科技有限公司 2024-02-13 CN disclosed
WO-2022257986-A1 USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME 广州岐微生物医药科技有限公司 2022-12-15 WO disclosed
EP-1391327-A1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2004-02-25 EP disclosed
WO-2003057210-A1 COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID KIMBERLY-CLARK WORLDWIDE, INC. (US) 2003-07-17 WO disclosed
US-20030125264-A1 Methods For Treating Wounds KIMBERLY-CLARK WORLDWIDE, INC. 2003-07-03 US disclosed
US-6555523-B1 Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus CASCADE ESTATES LTD. (MU) 2003-04-29 US disclosed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP disclosed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125264-A1 Methods For Treating Wounds FGF2, MMP1, FIBP MAOB 652/4885CYP3A4 3010/4885TP53 841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.